Published 10/09/2025 17:40
The inauguration of the Institute for Biopharmaceutical Research, the result of the Pharmaceutical Joint Venture Biotech between Cuba and China, was described by the Cuban Prime Minister Eduardo Martínez Díaz as a milestone for joint research between the two countries. The purpose of the initiative is to develop innovative immunotherapies against cancer and neurodegenerative and autoimmune diseases, combining Chinese technology and Cuban scientific expertise.
During a visit to the premises, Martínez Díaz revealed that Cuba received about $ 200 million in support from the Asian country. The funds were mainly used to buy raw materials for the production of medicines on the island and to finance research and development projects.
Shared production and continuous innovation
According to the deputy premie, more than ten production units in China-some of Chinese ownership and other mixed-already manufacture genetic products used in the basic line of Cuban medicines. In addition, new cooperation fields were opened in solid waste management, telecommunications and telemedicine, with plans to install the first Cuba Digital Hospital in the next phase of the partnership.
President Miguel Díaz-Canel Bermúdez, who also visited the facilities in Beijing, praised the performance of Biotech Pharmaceutical.
“This is a company that never stops, which is constantly innovating, which always achieves results,” he said.
Growth and new investments
The Chinese director of Joint Venture, Ba Xianhong, stressed that sales of the company almost quadrupled since 2015, despite strong competition in the Chinese biopharmaceutical market. He also announced that new investments should triple productive capacity, reaching 4 million annual bottles.
Biotech Pharmaceutical already distributes innovative Cuban medicines to about 2,000 Chinese hospitals. Among the highlights of clinical research are Nimotuzumab, for different types of cancer; Italizumab, for acute respiratory discomfort syndrome; and Cimavax, focused on the treatment of lung cancer. Another advance is the development of the JY09 protein for type 2 diabetes.
Health and diplomacy in tune
For Mayda Mauri Pérez, president of the Business Business Group, Biotech Pharmaceutical represents a bilateral cooperation model that directly benefits the peoples of Cuba and China.
Díaz-Canel stressed that the next challenge is to expand exports to other markets, including ASEAN, Eurasian Economic Union, as well as Latin American, Caribbean and Africa countries.
“We must think great. This partnership not only strengthens our health systems, but it makes room for Cuba to occupy new niches in the competitive world biopharmaceutical market,” said the president.
Source: vermelho.org.br
